NTLAIntellia Therapeutics, Inc.
$13.08-16% 1Y
$13.08
$8.0452 weeks$27.98
Latest close: back above its 200-day averageOct 9, 2026what changed →
The financials
Intellia Therapeutics, Inc. by the numbers
Intellia Therapeutics, Inc. (NTLA) reported revenue of $7.7M in Q2 2026 (quarter ended Jun 30, 2026), down 46% from the same quarter a year earlier. That came with net loss of $107M. For the full year FY2025, revenue was $68M (+17% year on year) and net income −$413M. Its largest product in Q1 2023 (quarter ended Mar 31, 2023) was Research And Development Services at $41M, 100% of the disclosed total, well ahead of Research Materials Shippmet Services at 0.2%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $7.7M | $14M | −46% |
| Operating income | −$113M | −$110M | n/a |
| Net income | −$107M | −$101M | n/a |
| Diluted EPS | −$0.80 | −$0.98 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Research And Development Services | $41M | 100% |
| Research Materials Shippmet Services | $100K | 0.2% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2025Total $1.0M (+400%)
Segment Latestquarter on quarteryear on year
- Research Materials Shippmet Services$1.0M$1.0Mquarter on quarter +400%year on year n/a+400%n/a
On our screens:Most shorted stocks